Vital Therapies (NASDAQ:VTL) has been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.00.
Separately, ValuEngine raised shares of Vital Therapies from a “hold” rating to a “buy” rating in a research note on Thursday, April 4th.
Several hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP raised its position in shares of Vital Therapies by 42.5% during the 4th quarter. Two Sigma Investments LP now owns 208,872 shares of the company’s stock valued at $39,000 after buying an additional 62,284 shares during the period. Vanguard Group Inc increased its holdings in Vital Therapies by 11.1% in the 3rd quarter. Vanguard Group Inc now owns 1,481,908 shares of the company’s stock valued at $408,000 after purchasing an additional 148,016 shares during the last quarter. Virtu Financial LLC increased its holdings in Vital Therapies by 120.3% in the 4th quarter. Virtu Financial LLC now owns 310,499 shares of the company’s stock valued at $58,000 after purchasing an additional 169,530 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Vital Therapies in the 4th quarter valued at approximately $37,000. Finally, Geode Capital Management LLC increased its holdings in Vital Therapies by 99.7% in the 4th quarter. Geode Capital Management LLC now owns 682,934 shares of the company’s stock valued at $127,000 after purchasing an additional 340,970 shares during the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.
VTL opened at $24.12 on Friday. Vital Therapies has a 1-year low of $0.15 and a 1-year high of $9.75.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Monday, March 4th. The company reported ($0.06) earnings per share for the quarter.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc in June 2003. Vital Therapies, Inc was founded in 2003 and is based in San Diego, California.
Recommended Story: Penny Stocks
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.